Ethan Natelson, MD

Professor of Clinical Medicine, Institute for Academic Medicine
Full Member, Research Institute
Program Director, Transitional Year Residency, Department of Medicine
Houston Methodist
Weill Cornell Medical College


After completing his postdoctoral training at the Baylor College of Medicine in Houston,Texas, Dr. Natelson became an Instructor there in the Department of Medicine in 1972. He was promoted to Assistant Professor the following year, and Clinical Assistant Professor of Medicine in 1975. He also received a faculty appointment as a Clinical Associate Professor of Medicine from The University of Texas Health Science Center at Houston in 1975, an appointment he still holds today. Dr. Natelson first joined the active staff at Houston Methodist Hospital in 1972 and became the Director of the Translational Internship Program there in 2006. He became the Chair of the second Institutional Review Board at Houston Methodist Research Institute when it was established in 2009.

Description of Research

Dr. Natelson’s research focuses on the development and evaluation of novel cancer therapeutics, as well as investigations into possible environmental causes of various cancers.

Areas Of Expertise

Pancreatic cancer Myelodysplasia Sideroblastic erythropoiesis Myeloid leukemia Lymphohematopoietic malignancy

Does occupational exposure to formaldehyde cause hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells?
Mundt, KA, Gallagher, AE, Dell, LD, Natelson, EA, Boffetta, P & Gentry, PR 2017, Critical Reviews in Toxicology, vol 47, no. 7, pp. 592-602. DOI:

Skepticism, the trained eye, and the telltale clue
Natelson, EA 2016, Texas Heart Institute Journal, vol 43, no. 3, pp. 205-206. DOI:

Acquired myelodysplasia or myelodysplastic syndrome: Clearing the fog
Natelson, EA & Pyatt, D 2013, Advances in Hematology, vol 2013, 309637. DOI:

Successful long-term treatment of philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide
Ahn, IE, Natelson, E & Rice, L 2013, Clinical Lymphoma, Myeloma and Leukemia, vol 13, no. SUPPL. 2. DOI:

Extreme thrombocytosis and cardiovascular surgery: Risks and management
Natelson, EA 2012, Texas Heart Institute Journal, vol 39, no. 6, pp. 792-798.

Atypical Ringed Sideroblasts in Association with Trisomy 19 and Myelodysplasia
Muhyieddeen, K & Natelson, EA 2012, Comparative Clinical Pathology, vol 21, no. 2, pp. 223-225. DOI:

Temozolomide-induced myelodysplasia
Natelson, EA & Pyatt, D 2010, Advances in Hematology, vol 2010, 760402. DOI:

Is inhalation exposure to formaldehyde a biologically plausible cause of lymphohematopoietic malignancies?
Pyatt, D, Natelson, E & Golden, R 2008, Regulatory Toxicology and Pharmacology, vol 51, no. 1, pp. 119-133. DOI:

Benzene exposure and refractory sideroblastic erythropoiesis: Is there an association?
Natelson, EA 2007, American Journal of the Medical Sciences, vol 334, no. 5, pp. 356-360. DOI:

Benzene-induced acute myeloid leukemia: A clinician's perspective
Natelson, EA 2007, American Journal of Hematology, vol 82, no. 9, pp. 826-830. DOI:

Pregnancy-induced pancytopenia with cellular bone marrow: Distinctive hematologic features
Natelson, EA 2006, American Journal of the Medical Sciences, vol 332, no. 4, pp. 205-207. DOI:

Myelodysplasia with isolated trisomy 15: A 15-Year follow-up without specific therapy
Natelson, EA 2006, American Journal of the Medical Sciences, vol 331, no. 3, pp. 157-158. DOI:

Atypical mycobacterial infection in a patient with hairy cell leukemia
Trizna, Z, Tschen, J & Natelson, EA 2001, Cutis, vol 67, no. 3, pp. 241-242.

A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
Stehlin, JS, Giovanella, BC, Natelson, EA, De Ipolyi, PD, Coil, D, Davis, B, Wolk, D, Wallace, P & Trojacek, A 1999, International Journal of Oncology, vol 14, no. 5, pp. 821-831.

Multiple subcutaneous nodules on the torso and leg. Leukemia cutis.
Trizna, Z, Tschen, J & Natelson, EA 1998, Archives of dermatology, vol 134, no. 11.

A phase I clinical and pharmacological study of oral 9- nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
Verschraegen, CF, Natelson, EA, Giovanella, BC, Kavanagh, JJ, Kudelka, AP, Freedman, RS, Edwards, CL, Ende, K & Stehlin, JS 1998, Anti-Cancer Drugs, vol 9, no. 1, pp. 36-44. DOI:

Multiple subcutaneous nodules on the torso and leg
Trizna, Z, Tschen, J & Natelson, EA 1998, Archives of Dermatology, vol 134, no. 11, pp. 1477-1482.

Protocols for the treatment of human tumor xenografts with camptothecins
Giovanella, BC, Natelson, E, Harris, N, Vardeman, D & Stehlin, JS 1996, Annals of the New York Academy of Sciences, vol 803, pp. 181-187. DOI:

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents
Natelson, EA, Giovanella, BC, Verschraegen, CF, Fehir, KM, De Ipolyi, PD, Harris, N & Stehlin, JS 1996, Annals of the New York Academy of Sciences, vol 803, pp. 224-230. DOI:

Photophobia and thickened eyelids in a healthy-appearing nurse
Fernando Tschen, L, Tschen, JA, Natelson, EA & Fred, HL 1996, Hospital Practice, vol 31, no. 2, pp. 73-74.